Wells Fargo has initiated coverage on Arcellx Inc (ACLX) with an Overweight rating, marking the firm's first assessment of the company's investment potential. This decision comes as Arcellx, a clinical-stage biotechnology firm based in Redwood City, California, focuses on developing innovative immunotherapies for cancer and other incurable diseases.
Arcellx is currently valued at a market capitalisation of $4.3 billion, with a trailing twelve-month earnings per share (EPS) of -3.92. The company’s lead programme is anitocabtagene autoleucel, a BCMA-targeting CAR T-cell therapy being evaluated in pivotal Phase II and Phase III trials for relapsed or refractory multiple myeloma. Additionally, Arcellx is advancing two clinical-stage ARC-SparX programmes, targeting BCMA and CD123 in acute myeloid leukaemia and myelodysplastic syndrome.
Analyst ratings, including Wells Fargo's recent action, provide insights based on extensive research and financial modelling. However, such assessments are inherently subject to change as new information emerges, and they should not be the sole basis for investment decisions. Investors are advised to consider various factors, including company fundamentals and market trends, when evaluating potential investments.
The upcoming earnings report is scheduled for May 6, 2026, with an estimated EPS of -1.15 and revenue expectations of $6.4 million. Analysts currently maintain a consensus rating of Buy, with 9 Strong Buy, 13 Buy, and 3 Hold ratings among 25 total analysts as of December 1, 2025.